Olaparib is under clinical development by AstraZeneca and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II drugs for Malignant Mesothelioma have a 42% phase ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The Australian government announces Olaparib now available on the PBS for HER2-negative metastatic breast cancer patients with mutated BRCA1 or BRCA2 gene.

Australians with prostate and breast cancer now have affordable access to affordable new and expanded medicines under the ...

The presence of BRCAm makes patients eligible for targeted treatment with agents like PARP inhibitors, including AZ's widely-used Lynparza (olaparib), which is approved for a range of BRCA-mutated ...

December 11, 2024--Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA® (olaparib) demonstrated ...

and chemotherapy followed by Lynparza (olaparib) maintenance therapy with or without bevacizumab in patients with advanced epithelial ovarian cancer without BRCA mutations. Compared to ...

Genetic testing can help spot an issue before it happens. In some places, testing for the BRCA gene can be expensive, but other women aren't aware it's an option. Dr. Olga Muldoon, a complex ...

Until recently, this test could not be performed in Nepal, according to an official from the National Public Health Laboratory. Santosh Subedee, Deputy Medical Chief of the Laboratory, told THT ...

In 2023, the global breast cancer drug market is projected to be worth USD 10,733.1 million.  Between 2023 and 2033, the demand for breast cancer drugs is expected to expand at a CAGR of 1.1%, ...